| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7396841 | TAKEDA PHARMS NA | Injections |
Aug, 2021
(2 years ago) | |
|
US7396841 (Pediatric) | TAKEDA PHARMS NA | Injections |
Feb, 2022
(2 years ago) | |
Prevacid Iv is owned by Takeda Pharms Na.
Prevacid Iv contains Lansoprazole.
Prevacid Iv has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Prevacid Iv are:
- US7396841
- US7396841*PED
Prevacid Iv was authorised for market use on 27 May, 2004.
Prevacid Iv is available in injectable;intravenous dosage forms.
Prevacid Iv can be used as when patients are unable to take the oral formulations, prevacid iv, for injection is indicated as an alternative for the short-term treatment (up to 7 days) of all grades of erosive esophagitis.
The generics of Prevacid Iv are possible to be released after 17 February, 2022.
Drugs and Companies using
LANSOPRAZOLE ingredient
Market Authorisation Date:
27 May, 2004Treatment:
When patients are unable to take the oral formulations, prevacid iv, for injection is indicated as an alternative for the short-term treatment (up to 7 days) of all grades of erosive esophagitisDosage:
INJECTABLE;INTRAVENOUS
More Information on Dosage
PREVACID IV family patents
